Dimeric procyanidin B2 inhibits constitutively active NF-kappaB in Hodgkin's lymphoma cells independently of the presence of IkappaB mutations.

@article{Mackenzie2008DimericPB,
  title={Dimeric procyanidin B2 inhibits constitutively active NF-kappaB in Hodgkin's lymphoma cells independently of the presence of IkappaB mutations.},
  author={Gerardo G Mackenzie and Ana Mar{\'i}a Adamo and Noah P Decker and Patricia I Oteiza},
  journal={Biochemical pharmacology},
  year={2008},
  volume={75 7},
  pages={1461-71}
}
Due to long-term toxicity of current Hodgkin's lymphoma (HL) treatment, the present challenge is to find new therapies that specifically target deregulated signaling cascades, including NF-kappaB, which are involved in Hodgkin (H) and Reed-Sternberg (RS) cell proliferation and resistance to apoptosis. We previously presented evidence that dimeric procyanidin B2 (B2) can interact with NF-kappaB proteins inhibiting the binding of NF-kappaB to DNA. Herein, we investigated if B2, acting at a late… CONTINUE READING

From This Paper

Figures, tables, results, connections, and topics extracted from this paper.
14 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…